Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 , A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa

Paradigm Therapeutics, Inc. South Carolina

View original content:https://www.prnewswire.com/news-releases/paradigm-therapeutics-inc-announces-investment-by-eshelman-ventures-llc-to-support-completion-of-development-of-sd-101-zorblisa-a-topical-therapy-for-treatment-across-the-entire-skin-surface-of-all-subtypes-of-epidermolysis-302443407.html